Glomerular filtration rate in patients with spondiloarthritis against the ackground of long-term therapy with NSAIDS -results of prospective observational study


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. evaluation of the changes in glomerular filtration rate (GFR) in patients with spondyloarthritis (Spa) taking nonsteroidal anti-inflammatory drugs (nsaids) for a long time. materials and methods. a prospective observational study included 82 patients with spa who took nsaids for a long time. gfr was assessed at baseline and over time every 24-зо weeks. for the safety of treatment, a patient with a decrease in gfr of less than 90 ml/min/1.73 m2 was excluded from the study and transferred to another therapy. patients took nsaids in two regimens: continuous regular intake of nsaids and continuous irregular intake of fixed or arbitrary doses of nsaids (continuous intermittent intake). results. the mean gfr for the entire group of patients was 104.8 [94.6; 118.2] ml/min/1.73 m2. after 6-12 months of followup, the mean gfr in 68 patients was 95.5 [85.5; iio.O] ml/min/1.73 m2 (P = о.оз2 relative to the baseline mean gfr in these 68 patients), 15 patients showed a decrease in gfr of less than 90 ml/min/1.73 m2. these patients were excluded from the study. after 12-18 months of follow-up, the remaining 53 patients had an mean gfr of ioi.o [86.0; iii.O] ml/min/1.73 m2 (P>o.05 relative to the previous level), 18 patients showed a decrease in gfr less than 90 ml/min/1.73 m2. after 18-24 months of follow-up, the mean gfr was 102.о [91.0; ii9.0] ml/min/1.73 m2 (P>o.05); the decrease in gfr less than 90 ml/min/1.73 m2 was not identified. further, only 22 patients took part in the study, their mean gfr after 24-зо months of follow-up was 106.о [106.0; ii8.5] ml/min/1.73 m2 (P>o.05 relative to baseline level). the features of gfr changes with different nsaid intake were revealed. conclusion. observational study revealed that in patients with spa with initially unimpaired gfr, taking nsaids for a long time (at least 2 years), gfr may not change significantly and remain normal. Against the background of long-term therapy with nsaids, some patients with spa may have a decrease in gfr of less than ml/min/1.73 m2, but no severe kidney injury was noted. with dynamic follow-up, it was found that in patients taking nsaids in an intermittent mode, a decrease in gfr occurs more often than in patients taking nsaids regularly.

Full Text

Restricted Access

About the authors

A. P Rebrov

Saratov State Medical University named after V.l. Razumovsky

Email: andreyrebrov@yandex.ru
Dr.Sci. (Med,), Professor, Head of the Department of Hospital Therapy, Faculty of General Medicine Saratov, Russia

A. V Aparkina

Saratov State Medical University named after V.l. Razumovsky

Email: alena437539@yandex.ru
Cand. Sci. (Med.), Teaching Assistant at the Department of Hospital Therapy, Faculty of General Medicine Saratov, Russia

References

  1. Guillherme Nobre Cavalcanti Lucas, Ana Carla Carneiro Leitao, Renan Lima Alencar, et. al. Pathophysiological aspects of nephropathy caused by nonsteroidal anti-inflammatory drugs. J. Bras. Nefrol. 2019;41(1):124-30. doi: 10.1590/2175-8239-JBN-2018-0107.
  2. Bindu S., Mazumder S., Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem. Pharmacol. 2020;180:114147. doi: 10.1016/.bcp.2020.114147.
  3. Davison S.N. Pain, analgesics, and safety in patients with CKD. Clin. J. Am. Soc. Nephrol. 2015;10(3):350-52. doi: 10.2215/CJN.00600115.
  4. Clave S, Rousset-Rouviere C., Laurent D., Tsimaratos M. The Invisible Threat of Non-steroidal Anti-inflammatory Drugs for Kidney. Front. Pediatr. 2019;7:520. doi: 10.3389/fped.2019.00520.
  5. Lefebvre С, Hindie J., Zappitelli M., et al. Non-steroidal anti-inflammatory drugs in chronic kidney disease: a systematic review of prescription practices and use in primary care. Clin. Kidney J. 2020;13(1):63-71.
  6. van der Heijde D., Ramiro S., Landewe R., et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. 2017;76(6):978-91. doi: 10.1136/annrheumdis-2016-210770.
  7. Blachier M., Canoui'-Poitrine F., Dougados M., et al. Factors associated with radiographic lesions in early axial spondyloarthritis. Results from the DESIR cohort. Rheumatol. (Oxford). 2013;52(9):1686-93. Doi: 10.1093/ rheumatology/ket207.
  8. Гайдукова И.З., Ребров А.П., Лапшина С.А. и др. Применение нестероидных противовоспалительных препаратов и генноинженерных биологических препаратов для лечения аксиальных спондилоартритов. Рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2017;55(5):474-84.
  9. Мухин Н.А., Моисеев С.В., Фомин В.В. Снижение скорости клубочковой фильтрации - общепопуляционный маркер риска сердечно-сосудистых осложнений. Вестник РАМН. 2010;12:40-3.
  10. Michener K.H., et al. Aortic Stiffness and Kidney Disease in an Elderly Population. Am. J. Nephrol. 2015;41(4-5):320-28
  11. Гайдукова И.З., Ребров А.П., Лебединская О.А., Акулова А.И., Апаркина А.В. Кардиоваскулярная заболеваемостьи смертность при анкилозирующем спондилите и псориатическом артрите - результаты одноцентрового четырехлетнегонаблюдения. Практич. медицина. 2015;2(88):123- 29
  12. Levey A.S., Stevens L.A., Schmid C.H., et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 2009;150(9):604-12
  13. Гайдукова И.З., Ребров А.П., Оттева Э.Н. и др. Применение нестероидных противовоспалительных препаратов для лечения аксиальных спондилоартритов, включая анкилозирующий спондилит, мониторинг эффективности и безопасности (проект рекомендаций группы экспертов по диагностике и лечению спондилоартритов). Научно-практическая ревматология. 2016;54(1):67-74. doi: 10.14412/1995-4484-2016-1S-67-74
  14. Bakland G., Gran J.T., Nossent J.C. Increased mortality in ankylosing spondylitis is related to disease activity. Ann. Rheum. Dis. 2011;70(11):1921- 25. doi: 10.1136/ard.2011.151191

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies